Session 1 – Liquid Profiling by Protein Markers

Chairs: S. Holdenrieder, M. Kowalewska

A new era of biomarkers: translational strategies to impact cancer care
Stefan Holdenrieder (DEU)

Recent advances in the use of biochemical tumor markers in cancer practice

Qing Meng (USA)

Integrated diagnostics in oncology: bridging tumor markers with molecular testing and imaging through clinical case studies

Tomris Ozben (TUR)

Multiplex protein imaging in tumour biology

Bernd Bodenmiller (CHE)

Session 2 – Liquid Profiling by Nucleic Acid Markers

Chairs: L. Looijenga, E. Heitzer

Liquid insights – ctDNA as a powerful tool for precision oncology

Ellen Heitzer (AUT)

Clinical application of plasma ctDNA in early cancer detection

Aviad Zick (ISR)

Multicancer early detection (MCED) approaches

NN

Characterization of posttranslational histone modifications on circulating nucleosomes

Axel Imhof (DEU)

Session 3 – Evidence-based Medicine (WHO IARC IC3R)
Chairs: D. Lokuhetty, I. Indave

The mission of IARC IC3R in Cancer Classification

Dilani Lokuhetty (LKA)

Mapping the Evidence for the WHO Classification of Tumours: a Living Evidence Gap Map

Iciar Indave (FRA)

EppiMapper: a novel tool for coding studies according study design

Fiona Campbell (GBR)

A new Hierarchy of Evidence for Tumours in Pathology (HETP)

Richard Collings (GBR)

Development of a decision tree for accurate coding of study types

Elena Beriso (ESP)

Establishment and interpretation of evidence gap maps

Magdalena Chechlinska (POL)

Molecular-based classification of cancers

Jennelle Hodge (USA)

Session 4 – Urological Cancers
Chairs: R. Kucera, M. Garrido

PROBASE: A risk-adapted German screening programme for prostate cancer

Peter Albers (DEU)

Predictive and prognostic biomarkers in urological cancers

Christopher Poremba (DEU)

Comprehensive genomic characterization of bladder cancer in tissue and blood

Iver Nordentoft (DNK)

Molecular patterns in testicular cancer

Leendert Looijenga (NLD)

Session 5 – Biobanking and Study Networks (BBMRI-ERIC)
Chairs: J. Habermann, M. Kiehntopf

BBMRI-ERIC – an exciting resource for biomarker research

Jens Habermann (AUT)

CanServe – a European study network for connected research

NN

Hospital-integrated Biobanking 2.0

Michael Kiehntopf (DEU)

Biobank network in the Czech Republic

Judita Kinkorova (CZE)

Session 6 – Gynecological Cancers
Chairs: V. Kulasingam, J. Osredkar

The SURVIVE study – Re-evaluating standard surveillance in early breast cancer survivors using liquid biopsies

Sabine Heublein (DEU)

Multiplex proteomics for tailored ovarian cancer monitoring

Vathany Kulasingam (CAN)

Prognostic role of CA-125 elimination rate constant (KELIM) in patients with advanced epithelial ovarian cancer

Josko Osredkar (SVN)

Effect of molecular characterization of endometrial cancer on the way of treatment

Leon Meglic (SVN)

Dysbiosis, immunity, and biomarkers: unraveling the molecular landscape of vulvar carcinoma

Magdalena Kowalewska (POL)

Session 7 – Gastrointestinal Cancers
Chairs: V. Heinemann, S. Böck

Guiding targeted and immune therapies in gastrointestinal cancers

Volker Heinemann (DEU)

Requirements for liquid profiling diagnostics in gastrointestinal cancers

NN

Molecular surgery – a novel concept with clinical implications

Martin Angele (DEU)

Circulating autoantibodies in pancreatic cancer: from tumor biology to clinical application

Xu Qian (CHN)

Session 8 – Epigenetic Biomarkers
Chairs: R. Schneider, M. Sanchez-Carbayo

Disrupted epigenetics: mechanisms of cancer disease

Robert Schneider (DEU)

Novel insights from the DNA methylome atlas

Natanel Loyfer (ISR)

Birthdating of pediatric tumors

Stefan Pfister (DEU)

Single-molecule, multi-modal, analysis of the epigenetics of plasma isolated nucleosomes

Efrat Shema (ISR)

Session 9 – Therapy Response Monitoring

Chairs: N. Normanno, M. Chechlinska

ctDNA analysis for therapy monitoring and MRD detection

Nicola Normanno (ITA)

IMPROVE-IT2: Optimization of (post) operative treatment in colorectal cancer by plasma ctDNA

Kåre Andersson Gotschalck (DNK)

Implementation of tumor marker-based algorithms in therapy monitoring

Freek van Delft (NLD)

Pharmacometric models to support individual dosing

Oliver Scherf-Clavel (DEU)

Session 10 – Extracellular Vesicles (GSEV)

Chairs: M. Pfaffl, K. Menck

Analysis of plasma extracellular vesicles using flow cytometry for cancer diagnostics

Kerstin Menck (DEU)

Detection and monitoring of cancer using activity-based biomarkers from plasma extracellular vesicles

Jan van Deun (NLD)

Monitoring glioblastoma beyond MRI via serum extracellular vesicle profiling

Katrin Reiners (DEU)

Identification of new druggable cancer targets by using extracellular vesicles

Kathrin Gaertner (DEU)

Session 11 – Lung Cancer

Chairs: H. van Rossum, M. van den Heuvel

A lab perspective of lung cancer tumor markers

Huub van Rossum (NLD)

Modeling strategies combining changes in multiple biomarkers for therapy monitoring

Michel van den Heuvel (NLD)

Tumor marker-based algorithms for therapy prediction and prognosis in NSCLC and SCLC

Thomas Muley (DEU)

Biomarkers for immunotherapy monitoring in lung cancer

David Lang (NLD)

Session 12 () – Molecular Pathology
Chairs: C. Poremba, S. Holdenrieder 

Immune signals in cancer

Jürgen Ruland (DEU)

Role of molecular biomarkers in immune and cellular therapies

Sebastian Stintzing (to be confirmed)

ExLiquid: exploiting liquid biopsies to advance cancer precision medicine

Christof Winter (DEU)

Fragmentomics and multimodal ctDNA diagnostics

Tina Moser (AUT)

Session 13 () – Moving Ahead - Precision Medicine 2.0

Chairs: B. Westphalen, S. Lange

Molecular prevention – where do we stand?

Michael Quante (DEU)

Beyond genomics – novel biomarkers on the verge of clinical relevance

Eva Wardelmann (to be confirmed)

AI biomarkers – transforming personalized healthcare?

Kristian Unger (DEU)

Innovative endpoints for trials in precision medicine

Maike Collienne (to be confirmed)

Session 14 () – Hematological cancers
Chair: T. Haferlach

Artificial Intelligence in pathology: transforming diagnosis and discovery

Andreas Mock (DEU)

AI-empowered computational pathology tools for precision oncology

Tingying Peng (CHN)

Biomarkers in hematology diagnosis with therapy implications

Gregor Hoermann (AUT)

MRD in flow cytometry and molecular genetics

Carsten Spiekermann (DEU)

Session 15 – Multimodal and Integrated Diagnostics

Chairs: V. Haselmann, C. Winter

Integrative ctDNA diagnostics in personalized cancer patient care

Verena Haselmann (DEU)

Integrative imaging-based diagnostics for personalized cancer patient care

Matthias Froelich (DEU)

Diagnosing with words – Large Language Models in medicine

Daniel Truhn (DEU)

LLM-based tumor-agnostic diagnostics

NN

Session 16 – New Biomarkers and Applications (EGTM)

Chairs: V. Barak, P. Oehr

EGTM sets standards for established and new tumor markers

Vivian Barak (ISR)

Circulating tumor DNA: Will it replace standard cancer biomarkers?

Michael Duffy (IRL)

Early detection of multiple cancer types using breath samples

Reef Einoch Amor (ISR)

Resistance to endocrine therapy and CDK4/6 inhibitors in advanced ER+/HER2- breast cancer

Andrea Nicolini (ITA)

Session 17 – Standardization and Harmonization (IFCC, GenomeMet)

Chairs: H. van Rossum, Q. Meng

The IFCC initiative of harmonization of tumor markers

Huub van Rossum (NLD)

LC-MS based reference methods for tumor markers

Daan van de Kerkhoff (NLD)

Optimizing biochemical tumor marker testing and interpretation: a CLSI guideline-based approach

Qing Meng (USA)

The GenomeMET project: approaches for standardization of liquid biopsy and genomic profiling methods

Alison Devonshire (GBR)

Ensuring accurate patient results for cancer patients - EQA for liquid biopsy testing

Jenni Fairley (GBR)